Issue 3/2015
Content (11 Articles)
Psychiatrists’ self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies
Daniela Reich-Erkelenz, Andrea Schmitt, Peter Falkai
S3 guideline on psychosocial therapies in severe mental illness: evidence and recommendations
Uta Gühne, Stefan Weinmann, Katrin Arnold, Thomas Becker, Steffi G. Riedel-Heller
Stigmatization of psychiatrists and general practitioners: results of an international survey
Wolfgang Gaebel, Harald Zäske, Jürgen Zielasek, Helen-Rose Cleveland, Kathrin Samjeske, Heather Stuart, Julio Arboleda-Florez, Tsuyoshi Akiyama, Anja E. Baumann, Oye Gureje, Miguel R. Jorge, Marianne Kastrup, Yuriko Suzuki, Allan Tasman, Thiago M. Fidalgo, Marek Jarema, Sarah B. Johnson, Lola Kola, Dzmytry Krupchanka, Veronica Larach, Lyndy Matthews, Graham Mellsop, David M. Ndetei, Tarek A. Okasha, Ekaterina Padalko, Joyce A. Spurgeoun, Magdalena Tyszkowska, Norman Sartorius
Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011
Anna K. Holl, Renate Grohmann, Martin Letmaier, Annamaria Painold, Sabrina Mörkl, Sermin Toto, Siegfried Kasper
Preventing compulsory admission to psychiatric inpatient care using psycho-education and monitoring: feasibility and outcomes after 12 months
Barbara Lay, Christina Blank, Silke Lengler, Thekla Drack, Marco Bleiker, Wulf Rössler
1H-magnetic resonance spectroscopy in obsessive–compulsive disorder: effects of 12 weeks of sertraline treatment on brain metabolites
Raşit Tükel, Kubilay Aydın, Erhan Ertekin, Seda Şahin Özyıldırım, Mehmet Barburoğlu
Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients
Jan Malte Bumb, Suna Su Aksay, Christoph Janke, Laura Kranaster, Olga Geisel, Peter Gass, Rainer Hellweg, Alexander Sartorius
Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?
Jochen Antel, Özgür Albayrak, Gerd Heusch, Tobias Banaschewski, Johannes Hebebrand
Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia
Kuan-Ju Chou, Hsing-Kang Chen, Chih-Hung Hung, Tzu-Ting Chen, Chun-Ming Chen, Bo-Jian Wu
Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis
Taro Kishi, Nakao Iwata
T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis
A. Eden Evins, L. Elliot Hong, Deanna L. Kelly